67-6

55/93

Miyazaki T, Ishiyama K, Kiyota M, Matsuoka H, Ichinohe T, Fukuda T, Atsuta Y, Suzumiya J, Suzuki R: Effect of allogeneic hematopoi-etic cell transplantation for patients with T-prolymphocytic leukemia: a retrospective study from the Adult Lymphoma Working Group of the Japan Society for hematopoietic cell transplantation. Ann Hematol. 2019; 98: 2213-2220.) Maekawa T, Kato S, Kawamura T, Takada K, Sone T, Ogata H, Saito K, Izumi T, Nagao S, Takano K, Okada Y, Tachi N, Teramoto M, Horiuchi T, Hikota-Saga R, Endo-Umeda K, Uno S, Osawa Y, Kobayashi A, Kobayashi S, Sato K, Hashimoto M, Suzu S, Usuki K, Morishita S, Araki M, Makishima M, Komatsu N, Kimura F: Increased SLAMF7highmono-cytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab. Blood. 2019; 134: 814-825.) Hayashi Y, Harada Y, Kagiyama Y, Nishi-kawa S, Ding Y, Imagawa J, Shingai N, Kato N, Kitaura J, Hokaiwado S, Maemoto Y, Ito A, Matsui H, Kitabayashi I, Iwama A, Komatsu N, Kitamura T, Harada H: NUP98-HBO1-fu-sion generates phenotypically and genetically relevant chronic myelomonocytic leukemia pathogenesis. Blood Adv. 2019; 3:1047-1060.) Inano T, Araki M, Morishita S, Imai M, Yasuda H, Nitta H, Ito M, Edahiro Y, Ochiai T, Misawa K, Fukuda Y, Ohsaka A, Komatsu N: JAK2 exon 12 mutation in myelodysplastic/myeloproliferative neoplasm with ring sidero-blasts and thrombocytosis: Not an exclusive mutation to polycythaemia vera. Br J Haematol. 2019; 187: e27-e31.) Tsukune Y, Sasaki M, Komatsu N. Reactiva-tion of Hepatitis B Virus in Patients with Multiple Myeloma. Cancers (Basel). 2019; 11: 1819.) Edahiro Y, Araki M, Inano T, Ito M, Morishita S, Misawa K, Fukuda Y, Imai M, Ohsaka A, Komatsu N: Clinical and molecular features of patients with prefibrotic primary myelofi-brosis previously diagnosed as having essen-tial thrombocythemia in Japan. Eur J Haematol. 2019; 102: 516-520.) Fukuda Y, Araki M, Yamamoto K, Morishita S, Inano T, Misawa K, Ochiai T, Edahiro Y, 3 4 5 6 7 8Imai M, Yasuda H, Gotoh A, Ohsaka A, Komatsu N: Evidence for prevention of renal dysfunction associated with primary myelofi-brosis by cytoreductive therapy. Haemato-logica. 2019; 104: e506-e509.) Iriyama N, Tokuhira M, Sato E, Sugimoto K-J, Takaku T, Ishikawa M, Nakazato T, Fujita H, Kimura Y, Fujioka I, Asou N, Komatsu N, Kizaki M, Hatta Y, Kawaguchi T: Smoking influences the outcomes of patients receiving tyrosine kinase inhibitors for chronic myeloid leukemia in the chronic phase: A retrospective analysis. Hematol Oncol. 2019; 37: 323-325. 9 10) Hatsumi N, Miyawaki S, Yamauchi T, Takeshita A, Komatsu N, Usui N, Arai Y, Ishida F, Morii T, Kano Y, Ogura M, Machida S, Nishii K, Honda S, Ohnishi K, Naoe T: Phase II study of FLAGM (fludarabine + high-dose cytara-bine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia. Int J Hematol. 2019; 109: 418-425. 11) Yasuda H, Tsutsui M, Ando J, Inano T, Noguchi M, Yahata Y, Tanaka M, Tsukune Y, Masuda A, Shirane S, Misawa K, Gotoh A, Sato E, Aritaka N, Sekiguchi Y, Sugimoto K, Komatsu N: Vitamin B6 deficiency is preva-lent in primary and secondary myelofibrosis patients. Int J Hematol. 2019; 110: 543-549. 12) Kurosawa S, Sekiya N, Doki N, Yaguchi T, Kishida Y, Nagata A, Yamada Y, Konishi T, Kaito S, Yoshifuji K, Shirane S, Uchida T, Inamoto K, Toya T, Igarashi A, Najima Y, Muto H, Kobayashi T, Kakihana K, Sakamaki H, Ohashi K: The emergence of rare nocardi-osis following allogeneic hematopoietic stem cell transplantation in the era of molecular taxonomy. Int J Infect Dis. 2019; 89: 154-162. 13) Tsukune Y, Sasaki M, Isoda A, Ando J, Koike M, Matsumoto M, Sawamura M, Tamura H, Handa H, Imai Y, Yahata Y, Komatsu N. Safety of lenalidomide, dexamethasone, and cyclo-phosphamide in elderly Japanese patients with relapsed and refractory multiple myeloma: results of phase 1 study. International Journal of Myeloma. 2019; 9: 1-6. 14) Yokomizo T, Watanabe N, Umemoto T, Matsuo J, Harai R, Kihara Y, Nakamura E, Tada N, 563